Optimized dosing for drug coated stents

• US 7,906,133 B2
• Filed: 05/11/2005
• Issued: 03/15/2011
• Est. Priority Date: 09/24/2001
• Status: Active Grant

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Inventors: Barry, James J., Kamath, Kalpana R.
• Primary Examiner(s): Sajjadi; Fereydoun G
• Assistant Examiner(s): BROWN, COURTNEY A
• Application Number:
  US11/127,499
• Publication Number:
  US 20050202061A1
• Time in Patent Office: 2,134 Days
• Field of Search: 424/422, 424/423, 514/277, 514/449
• US Class Current: 424/423
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The inventors have found that both the drug dose and drug release profiles are significant factors for the safety and efficacy of drug coated stents. The inventors have identified optimum dosing and release kinetics for drug coated stents. In particular, the inventors have determined dosing and release kinetics that permit the delivery of the lowest effective drug dosage, thus enhancing patient safety and minimizing any side effects from the drug.

Claims

1. A drug coated stent comprising:

a structural member insertable into a body lumen of a patient; and

a drug coated onto at least a portion of said structural member;

wherein about 60 micrograms or less than 60 micrograms of the drug is released within ten days after insertion into the body lumen of the patient and

the release rate is maximized between 24 hours and three days.

2. The drug coated stent of claim 1, wherein said drug comprises paclitaxel.

3. The drug coated stent of claim 1, wherein said drug is incorporated into a polymer carrier coated onto at least a portion of said structural member.

4. The drug coated stent of claim 3, wherein said polymer comprises styrene.

5. The paclitaxel coated stent of claim 2, wherein about 20 micrograms or less than 20 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

6. The paclitaxel coated stent of claim 2, wherein about 15 micrograms or less than 15 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

7. The paclitaxel coated stent of claim 2, wherein about 10 micrograms or less than 10 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

8. The paclitaxel coated stent of claim 2, wherein about 8 micrograms or less than 8 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

9. The paclitaxel coated stent of claim 2, wherein about 6 micrograms or less than 6 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

10. The paclitaxel coated stent of claim 2, wherein about 4 micrograms or less than 4 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

11. A paclitaxel coated stent comprising:

a structural member insertable into a body lumen of a patient; and

paclitaxel coated onto at least a portion of said structural member;

wherein about 10 micrograms or less than 10 micrograms of paclitaxel is released from said stent two days after exposure to an aqueous environment and

the release rate is maximized between 24 hours and three days.

12. The paclitaxel coated stent of claim 11, wherein about 5 micrograms or less than 5 micrograms of paclitaxel is released from said stent two days after exposure to an aqueous environment.

13. The paclitaxel coated stent of claim 11, wherein about 2 micrograms or less than 5 micrograms of paclitaxel is released from said stent two days after exposure to an aqueous environment.